MetaCap

Aquestive Therapeutics (AQST) vs Indaptus Therapeutics (INDP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 52.4% versus a loss of 39.5%. Over five years, AQST leads with a -45.7% price change compared with -98.3% for INDP. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $433.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%INDP+52.43%
+167%+54%-60%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%INDP-98.22%
+24%-40%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus INDP key metrics
MetricAQSTINDP
Share price$3.46$2.82
Market cap$434.88M$433.16M
1-day change-6.61%-9.90%
YTD return-46.44%-3.09%
1-year return-39.51%+52.43%
5-year return-45.68%-98.26%
EPS (TTM)$-0.65$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M—
Revenue growth (YoY)-22.61%—
Net income (latest FY)$-83.78M$-20.85M
Gross margin58.35%—
Operating margin-159.50%—
Net margin-188.09%—
52-week high$6.74$5.96
52-week low$2.93$0.92
Distance from 52-week high-48.63%-52.68%
Analyst consensusstrong_buy—
Avg. price target upside+169.65%—
Average volume2.41M712.87K
Shares outstanding125.69M153.60M
Employees1475
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed AQST by 91.9 percentage points over the past year.

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

AQST vs INDP FAQ

Which is bigger, Aquestive Therapeutics or Indaptus Therapeutics?

Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $433.16M for Indaptus Therapeutics (INDP).

Which stock has performed better over the past year, AQST or INDP?

INDP returned +52.43% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and Indaptus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons